Answers are grounded in this paper and cite their sources.
ABSTARCT Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, therapy-resistant stage of prostate cancer driven by complex oncogenic signaling. This study applied an integrated computational framework to evaluate CHEMBL100076, a quinoline-3-carbonitrile derivative, as a potential multi-target inhibitor for mCRPC. Network pharmacology identified 55 core protein targets, including key hubs such as AR, EGFR, and SRC, implicated in cancer-related pathways. Molecular docking revealed strong binding affinities to AR, EGFR, SRC, GSK3B, and ESR1, while 100ns molecular dynamics simulations confirmed stable protein-ligand interactions. These findings support CHEMBL100076 as a promising Polypharmacology candidate for mCRPC treatment.
No takes yet. Share an insight, caveat, or question.
Emmanuel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: